
Krystal Biotech (KRYS) Stock Forecast & Price Target
Krystal Biotech (KRYS) Analyst Ratings
Bulls say
Krystal Biotech is well positioned fundamentally because VYJUVEK continues to compound, with Q3 worldwide revenue of $127 million, net profit of $63 million, gross margins of 94%, and over 760 U.S. reimbursement approvals, while ex-U.S. uptake is gaining traction in Germany, Italy, and Japan. Its outlook is further strengthened by a very strong balance sheet with $1.2 billion in cash, lower FY26 non-GAAP OpEx guidance of $155 million to $165 million, and a planned $400 million buyback, signaling both profitability and capital discipline. Beyond the core franchise, the patented HSV-1 platform is producing multiple shots on goal in NK, ocular DEB, CF, HHD, AATD, and oncology, with early efficacy and tolerability signals that could create meaningful long-term upside if later-stage data confirm benefit.
Bears say
Krystal Biotech is facing a weaker fundamental setup because multiple key clinical programs have slipped on enrollment, pushing Ph3 '801 and '407 and Ph3 '803 into 1H27 or later 2027, while EMERALD-1 now guides to 2027 data after slower-than-expected site activation and patient hesitancy. Although Q3 net Vyjuvek revenue of $127M and EPS of $2.05 met consensus, growth is being pressured by ex-U.S. launch frictions, including France’s hospital-based GMO administration, Japan’s twice-monthly represcribing requirement, and Italy’s delayed launch into early 2027. These delays reduce near-term visibility and increase execution risk across clinical, regulatory, and commercialization fronts, limiting confidence that the company can sustain the trajectory needed to meet longer-term financial projections.
This aggregate rating is based on analysts' research of Krystal Biotech and is not a guaranteed prediction by Public.com or investment advice.
Krystal Biotech (KRYS) Analyst Forecast & Price Prediction
Start investing in Krystal Biotech (KRYS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Krystal Biotech (KRYS) Forecast
Krystal Biotech (KRYS) Analyst Forecast & Price Prediction
Start investing in Krystal Biotech (KRYS)
Order type
Buy in
Order amount
Est. shares
0 shares